Histiocytic Disorders, Malignant clinical trials at UCSF

1 research study open to eligible people

Histiocytic disorders, malignant are rare diseases where certain immune cells grow uncontrollably. UCSF is conducting a study about cobimetinib, a drug used in people with Langerhans cell histiocytosis to see if it helps control the disease. This trial includes both children and adults with these histiocytic conditions.

Showing trials for

  • Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders

    open to all eligible people

    This is a research study of a drug called cobimetinib in children and adults diagnosed with Langerhans cell histiocytosis (LCH), and other histiocytic disorders that has returned or does not respond to treatment. Cobimetinib blocks activation of a protein called Mitogen-activated protein kinase (MEK) that is part of incorrect growth signals in histiocytosis cells. Four different groups of patients will be enrolled.

    San Francisco, California and other locations

Our lead scientists for Histiocytic Disorders, Malignant research studies include .

Last updated: